Genomic abnormalities in monoclonal gammopathy of undetermined significance

Blood

Volumn 100, Issue 4, 2002, Pages 1417-1424

  Fonseca, Rafael ^a,b   Bailey, Richard J ^a   Ahmann, Gregory J ^a   Vincent Rajkumar, S ^a   Hoyer, James D ^a   Lust, John A ^a   Kyle, Robert A ^a   Gertz, Morie A ^a   Greipp, Philip R ^a   Dewald, Gordon W ^a  

^a MAYO CLINIC   (United States)

^b Division of Hematology and Internal Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

ARTICLE; CHROMOSOME 13; CHROMOSOME ANALYSIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC ANALYSIS; GENOMICS; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS;

EID: 0037103287     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v100.4.1417.h81602001417_1417_1424     Document Type: Article

References (44)

1. Mouse c-myc oncogene is located on chromosome 15 and translocated to chromosome 12 in plasmacytomas
2. Translocation, breakage and truncated transcripts of c-myc oncogene in murine plasmacytomas
3. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines
4. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3
5. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma
6. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma
7. IgH translocations in multiple myeloma: A nearly universal event that rarely involves c-myc
8. Multiple myeloma: Increasing evidence for a multistep transformation process
9. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma
10. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32)
11. The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization
12. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma
13. Translocations at the IgH locus are possible early genetic events in patients with primary systemic amyloidosis
14. Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts
15. Translocation t(4;14)(p16.3;q32) is a recurrent genetic lesion in primary amyloidosis
16. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma
17. Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping
18. Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma
19. Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma
20. Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance
21. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma
22. Cytogenetic abnormalities in systemic amyloidosis; a comparison of conventional cytogenetic analysis to fluorescent in-situ hybridization with simultaneous cytoplasmic immunoglobulin staining
23. "Benign" monoclonal gammopathy after 20 to 35 years of follow-up
24. A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies
25. Monoclonal gammopathy of undetermined significance (MGUS)
26. A long-term study of prognosis in monoclonal gammopathy of undetermined significance
27. Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell
28. Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32)
29. Detection of 11q13 rearrangements in hematologic neoplasias by double-color fluorescence in situ hybridization
30. Direct visualization of dispersed 11q13 chromosomal translocations in mantle cell lymphoma by multicolor DNA fiber fluorescence in situ hybridization
31. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q-arm or monosomy
32. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta 13) in multiple myeloma: An eastern cooperative oncology group study
33. The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study
34. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma
35. Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13
36. The t(4;14)(p16.3; q32) is strongly associated with chromosome 13 abnormalities (Δ13) in both multiple myeloma (MM) and MGUS
37. Chromosomal abnormalities in systemic amyloidosis
38. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients
39. High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization
40. Genetic instability of cancer cells is proportional to their degree of aneuploidy
41. How aneuploidy may cause cancer and genetic instability
42. Cancer cell cycles
43. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts
44. Detection of cyclin D1 (bcl-1, PRAD1) overexpression by a simple competitive reverse transcription-polymerase chain reaction assay in t(11;14) (q13;q32)-bearing B-cell malignancies and/or mantle cell lymphoma